Premium
F5–02–02: Glucose metabolism in Alzheimer's disease: It's not just about energy
Author(s) -
Raichle Marc
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.04.456
Subject(s) - pentose phosphate pathway , carbohydrate metabolism , glycolysis , metabolism , oxidative phosphorylation , glucose uptake , glucose transporter , citric acid cycle , biology , anaerobic glycolysis , biochemistry , neuroprotection , chemistry , neuroscience , endocrinology , insulin
in clinically normal (CN) individuals have revealed associations between decreased gray matter volume and cerebral hypometabolism in parietotemporal and parahippocampal regions, suggesting that SCCmay coincide with early pathological changes.More recently, the relationship between A b burden, using 11 C PiB-PETamyloid imaging, and SCC has been investigated. Results: We, as well as another research group, have reported a significant relationship between SCC and cortical PiB binding in CN individuals. In particular, individuals who reported worse memory relative to their peers were more likely to have increased PiB retention. Additionally, a relationship between an individual’s self-report of decline on tasks that required higher-level cognitive processing (i.e., prioritizing and organizing tasks) was associated with amyloid burden. By contrast, informant report was not associated with increased PiB binding. Conclusions: Accumulating evidence suggests SCC may be an early indicator of AD pathology. The strength of the relationship between SCC and amyloid burden appears to depend on the types of questions used to assess subjective changes. Going forward, SCC that probe a range of cognitive functions that are framed relative to a reference group (self and/or age-matched peers) with consideration of temporal course may be important in understanding relationships to early AD pathology. Findings will provide critical information for future secondary prevention trials that will be seeking subjects at the preclinical stage of AD.